Buy or sell PathAI stock pre IPO via an EquityZen fund
PathAI is developing cutting-edge technology that promises to better diagnose—and treat—some of today's most challenging diseases.
About PathAI Stock
PathAI’s services solve the most challenging pathology problems faced by the research and pharmaceutical industry. The PathAI platform provides end-to-end automation for reliable, scalable, and cost-effective long-term solutions. PathAI is developing technology that assists pathologists in making rapid and accurate diagnoses for every patient, every time. The company was founded in 2016 and based in Boston, Massachusetts.
Co-founder & CEO
Co-founder & CTO
Senior Software Engineer
Independent Product Management Consultant